HC Wainwright Brokers Reduce Earnings Estimates for Travere Therapeutics, Inc. (NASDAQ:TVTX)

Travere Therapeutics, Inc. (NASDAQ:TVTX) – Analysts at HC Wainwright dropped their FY2026 earnings estimates for Travere Therapeutics in a report issued on Tuesday, May 7th. HC Wainwright analyst E. Arce now expects that the company will earn $0.13 per share for the year, down from their prior forecast of $0.20. HC Wainwright has a “Buy” rating and a $19.00 price target on the stock. The consensus estimate for Travere Therapeutics’ current full-year earnings is ($3.10) per share.

Travere Therapeutics (NASDAQ:TVTX) last issued its quarterly earnings data on Monday, May 6th. The company reported ($1.76) EPS for the quarter, missing analysts’ consensus estimates of ($0.98) by ($0.78). The business had revenue of $41.40 million during the quarter, compared to analysts’ expectations of $43.46 million. Travere Therapeutics had a negative return on equity of 177.97% and a negative net margin of 56.02%. The business’s quarterly revenue was up 34.0% on a year-over-year basis. During the same period in the previous year, the business earned ($1.27) earnings per share.

Other equities analysts have also recently issued reports about the stock. Wells Fargo & Company boosted their target price on shares of Travere Therapeutics from $8.00 to $9.00 and gave the company an “equal weight” rating in a research note on Friday, February 16th. Canaccord Genuity Group increased their target price on shares of Travere Therapeutics from $15.00 to $18.00 and gave the stock a “buy” rating in a research note on Tuesday. Guggenheim reissued a “neutral” rating on shares of Travere Therapeutics in a research report on Wednesday, March 27th. Piper Sandler raised their target price on shares of Travere Therapeutics from $10.00 to $11.00 and gave the company a “neutral” rating in a report on Thursday, January 18th. Finally, Wedbush reissued an “outperform” rating and set a $13.00 price objective on shares of Travere Therapeutics in a report on Wednesday, April 17th. Five investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $16.69.

Travere Therapeutics Trading Down 2.6 %

TVTX traded down $0.17 on Friday, reaching $6.43. 100,152 shares of the company traded hands, compared to its average volume of 1,268,153. The firm has a fifty day simple moving average of $6.97 and a two-hundred day simple moving average of $7.59. The company has a quick ratio of 3.41, a current ratio of 3.47 and a debt-to-equity ratio of 1.88. Travere Therapeutics has a one year low of $5.12 and a one year high of $19.54. The company has a market cap of $489.39 million, a P/E ratio of -4.10 and a beta of 0.69.

Institutional Investors Weigh In On Travere Therapeutics

Several institutional investors have recently bought and sold shares of the company. Signaturefd LLC grew its holdings in Travere Therapeutics by 1,656.4% in the 4th quarter. Signaturefd LLC now owns 3,021 shares of the company’s stock valued at $27,000 after buying an additional 2,849 shares in the last quarter. Nisa Investment Advisors LLC increased its stake in shares of Travere Therapeutics by 968.1% in the fourth quarter. Nisa Investment Advisors LLC now owns 5,650 shares of the company’s stock valued at $51,000 after buying an additional 5,121 shares during the period. China Universal Asset Management Co. Ltd. grew its stake in Travere Therapeutics by 353.3% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 8,690 shares of the company’s stock worth $78,000 after purchasing an additional 6,773 shares during the period. Dynamic Technology Lab Private Ltd acquired a new stake in Travere Therapeutics during the fourth quarter worth approximately $137,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in Travere Therapeutics by 32.0% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 16,511 shares of the company’s stock worth $148,000 after acquiring an additional 4,007 shares in the last quarter.

About Travere Therapeutics

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.